AP2015008202A0 - 4-Methyl-2,3,5,9,9B-PENTAAZA-cyclopenta[A] naphthalenes - Google Patents

4-Methyl-2,3,5,9,9B-PENTAAZA-cyclopenta[A] naphthalenes

Info

Publication number: AP2015008202A0
Authority: AP; ARIPO
Prior art keywords: pentaaza; naphthalenes; cyclopenta; methyl
Prior art date: 2012-07-31

Application number

AP2015008202A

Other languages

English (en)

Inventor

Christian Grunwald

Riccardo Giovannini

Barbara Bertani

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-31

Filing date

2013-07-29

Publication date

2015-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906250&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008202(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-29 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-31 Publication of AP2015008202A0 publication Critical patent/AP2015008202A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

AP2015008202A 2012-07-31 2013-07-29 4-Methyl-2,3,5,9,9B-PENTAAZA-cyclopenta[A] naphthalenes AP2015008202A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12178713		2012-07-31
PCT/EP2013/065894 WO2014019979A1 (en)	2012-07-31	2013-07-29	4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

Publications (1)

Publication Number	Publication Date
AP2015008202A0 true AP2015008202A0 (en)	2015-01-31

Family

ID=48906250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008202A AP2015008202A0 (en)	2012-07-31	2013-07-29	4-Methyl-2,3,5,9,9B-PENTAAZA-cyclopenta[A] naphthalenes

Country Status (28)

Country	Link
US (2)	US20140045856A1 (xx)
EP (1)	EP2882749B1 (xx)
JP (1)	JP6356671B2 (xx)
KR (1)	KR20150037950A (xx)
CN (1)	CN104428302B (xx)
AP (1)	AP2015008202A0 (xx)
AR (1)	AR091939A1 (xx)
AU (1)	AU2013298621B2 (xx)
BR (1)	BR112015002118A2 (xx)
CA (1)	CA2880447A1 (xx)
CL (1)	CL2015000096A1 (xx)
CO (1)	CO7310531A2 (xx)
EA (1)	EA028958B1 (xx)
EC (1)	ECSP15006871A (xx)
GE (1)	GEP201706707B (xx)
HK (1)	HK1208440A1 (xx)
IL (1)	IL236494A0 (xx)
MA (1)	MA37798B1 (xx)
MX (1)	MX2015000965A (xx)
NZ (1)	NZ703797A (xx)
PE (1)	PE20150706A1 (xx)
PH (1)	PH12015500211B1 (xx)
SG (1)	SG11201500772VA (xx)
TN (1)	TN2015000022A1 (xx)
TW (1)	TW201418255A (xx)
UA (1)	UA115561C2 (xx)
UY (1)	UY34955A (xx)
WO (1)	WO2014019979A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9540379B2 (en)	2011-01-31	2017-01-10	Boehringer Ingelheim International Gmbh	(1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
WO2013034761A1 (en) *	2011-09-09	2013-03-14	H. Lundbeck A/S	Pyridine compounds and uses thereof
US20140045856A1 (en) *	2012-07-31	2014-02-13	Boehringer Ingelheim International Gmbh	4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2016145614A1 (en)	2015-03-17	2016-09-22	Merck Sharp & Dohme Corp.	Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en)	2015-03-26	2021-08-11	Merck Sharp & Dohme Corp.	Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en)	2015-05-05	2019-02-05	Merck Sharp & Dohme Corp.	Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en)	2015-05-15	2016-11-24	Merck Sharp & Dohme Corp.	Pyrimidinone amide compounds as pde2 inhibitors
CN107614501B (zh) *	2015-05-20	2020-01-14	广东众生睿创生物科技有限公司	羟基嘌呤类化合物及其应用
WO2016191935A1 (en)	2015-05-29	2016-12-08	Merck Sharp & Dohme Corp.	6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en)	2015-06-04	2016-12-08	Merck Sharp & Dohme Corp.	Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en)	2015-06-25	2016-12-29	Merck Sharp & Dohme Corp.	Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en)	2015-07-01	2017-01-05	Merck Sharp & Dohme Corp.	Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en)	2015-07-01	2017-01-05	Merck Sharp & Dohme Corp.	Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en)	2015-10-13	2017-04-19	Boehringer Ingelheim International GmbH	Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
AU2017246334C1 (en) *	2016-04-04	2022-11-17	Sinopia Biosciences, Inc.	Treating extrapyramidal syndrome using Trapidil
AR112457A1 (es) *	2017-08-02	2019-10-30	Lilly Co Eli	Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AU2018371216A1 (en)	2017-11-23	2020-06-04	Oslo University Hospital Hf	Treatment of tachycardia

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000319278A (ja) *	1999-05-11	2000-11-21	Ono Pharmaceut Co Ltd	縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP2000319277A (ja) *	1999-05-11	2000-11-21	Ono Pharmaceut Co Ltd	縮合ピラジン化合物およびその化合物を有効成分とする薬剤
DE10108752A1 (de)	2001-02-23	2002-09-05	Bayer Ag	Neue Substituierte Imidazotriazinone
MXPA05010293A (es)	2003-03-27	2005-11-17	Pfizer Prod Inc	4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
WO2005041957A1 (en)	2003-10-29	2005-05-12	Pfizer Products Inc.	Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
BRPI0417663A (pt)	2003-12-16	2007-04-03	Pfizer Prod Inc	pirido[2,3-d]pirimidina-2,4diaminas como inibidores de pde 2
EP1548011A1 (en)	2003-12-23	2005-06-29	Neuro3D	Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
FR2865331A1 (fr)	2004-01-21	2005-07-22	France Telecom	Procede de connexion d'un reseau domestique a un serveur cops distant et dispositif associe
FR2870539B1 (fr)	2004-05-19	2006-08-04	Greenpharma Sa Sa	Nouvelles methodes et medicaments
CN101133057B (zh)	2004-09-02	2011-03-09	尼科梅德有限责任公司	***并酞嗪化合物
JP5130053B2 (ja)	2005-01-05	2013-01-30	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	トリアゾロフタラジン
EA012505B1 (ru)	2005-01-05	2009-10-30	Никомед Гмбх	Триазолофталазины в качестве ингибиторов pde-2
BRPI0502411A (pt)	2005-03-31	2006-11-28	Univ Minas Gerais	processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
JP2009523820A (ja)	2006-01-23	2009-06-25	アミラファーマシューティカルス，インコーポレーテッド	５−リポキシゲナーゼの三環系抑制剤
WO2007121319A2 (en)	2006-04-14	2007-10-25	University Of California	Compostions and methods for determining and predicting treatment responses for depression and anxiety
TW200817400A (en) *	2006-05-30	2008-04-16	Elbion Ag	Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en)	2006-05-30	2008-04-01	Elbion Ag	4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
DE102006048693A1 (de)	2006-10-14	2008-04-17	Bayer Healthcare Ag	Inhibition der PDE2A
CN101553491B (zh) *	2006-12-13	2013-05-29	Aska制药株式会社	喹喔啉衍生物
WO2009070583A1 (en) *	2007-11-30	2009-06-04	Wyeth	Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
TWI501965B (zh)	2008-06-20	2015-10-01	Lundbeck & Co As H	作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
AU2009291719A1 (en)	2008-09-10	2010-03-18	Alcon Research, Ltd	Heterocyclic inhibitors of histamine receptors for the treatment of disease
US8415386B2 (en)	2008-10-08	2013-04-09	Bristol-Myers Squibb Company	Azolopyrrolone melanin concentrating hormone receptor-1 antagonists
WO2010054253A1 (en)	2008-11-07	2010-05-14	Biotie Therapies Gmbh	Triazine derivatives as inhibitors of phosphodiesterases
WO2010104933A1 (en) *	2009-03-11	2010-09-16	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
EP2266985A1 (en) *	2009-06-26	2010-12-29	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Tricyclic Pyrimidine Derivatives as Wnt antagonists
US8765760B2 (en)	2011-01-11	2014-07-01	Sunovion Pharmaceuticals, Inc.	[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
US9540379B2 (en)	2011-01-31	2017-01-10	Boehringer Ingelheim International Gmbh	(1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
JP6115962B2 (ja)	2011-06-27	2017-04-19	ヤンセンファーマシューティカエヌ．ベー．	１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
WO2013034761A1 (en)	2011-09-09	2013-03-14	H. Lundbeck A/S	Pyridine compounds and uses thereof
WO2013034758A1 (en)	2011-09-09	2013-03-14	H. Lundbeck A/S	Substituted triazolopyrazines and uses thereof
AR088082A1 (es)	2011-10-13	2014-05-07	Lilly Co Eli	Moduladores selectivos del receptor androgeno
CA2872216C (en)	2012-06-26	2021-07-20	Janssen Pharmaceutica Nv	Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
US20140045856A1 (en) *	2012-07-31	2014-02-13	Boehringer Ingelheim International Gmbh	4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

2013
- 2013-07-18 US US13/945,008 patent/US20140045856A1/en not_active Abandoned
- 2013-07-26 US US13/951,531 patent/US9085584B2/en active Active
- 2013-07-29 WO PCT/EP2013/065894 patent/WO2014019979A1/en active Application Filing
- 2013-07-29 CN CN201380037349.6A patent/CN104428302B/zh not_active Expired - Fee Related
- 2013-07-29 AP AP2015008202A patent/AP2015008202A0/xx unknown
- 2013-07-29 GE GEAP201313748A patent/GEP201706707B/en unknown
- 2013-07-29 AU AU2013298621A patent/AU2013298621B2/en not_active Ceased
- 2013-07-29 JP JP2015524750A patent/JP6356671B2/ja active Active
- 2013-07-29 BR BR112015002118A patent/BR112015002118A2/pt not_active IP Right Cessation
- 2013-07-29 KR KR20157002607A patent/KR20150037950A/ko not_active Application Discontinuation
- 2013-07-29 EP EP13742632.6A patent/EP2882749B1/en active Active
- 2013-07-29 MX MX2015000965A patent/MX2015000965A/es unknown
- 2013-07-29 MA MA37798A patent/MA37798B1/fr unknown
- 2013-07-29 EA EA201500182A patent/EA028958B1/ru not_active IP Right Cessation
- 2013-07-29 CA CA2880447A patent/CA2880447A1/en not_active Abandoned
- 2013-07-29 NZ NZ703797A patent/NZ703797A/en not_active IP Right Cessation
- 2013-07-29 UA UAA201501673A patent/UA115561C2/uk unknown
- 2013-07-29 PE PE2015000102A patent/PE20150706A1/es not_active Application Discontinuation
- 2013-07-29 SG SG11201500772VA patent/SG11201500772VA/en unknown
- 2013-07-30 TW TW102127314A patent/TW201418255A/zh unknown
- 2013-07-30 AR ARP130102708A patent/AR091939A1/es unknown
- 2013-07-31 UY UY0001034955A patent/UY34955A/es unknown
2014
- 2014-12-28 IL IL236494A patent/IL236494A0/en unknown
2015
- 2015-01-14 CL CL2015000096A patent/CL2015000096A1/es unknown
- 2015-01-16 TN TNP2015000022A patent/TN2015000022A1/fr unknown
- 2015-01-29 CO CO15018184A patent/CO7310531A2/es unknown
- 2015-01-30 PH PH12015500211A patent/PH12015500211B1/en unknown
- 2015-02-25 EC ECIEPI20156871A patent/ECSP15006871A/es unknown
- 2015-09-11 HK HK15108887.2A patent/HK1208440A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ECSP15006871A (es)	2015-12-31
CA2880447A1 (en)	2014-02-06
NZ703797A (en)	2017-09-29
IL236494A0 (en)	2015-02-26
PE20150706A1 (es)	2015-06-03
GEP201706707B (en)	2017-07-25
MX2015000965A (es)	2015-04-10
TW201418255A (zh)	2014-05-16
WO2014019979A1 (en)	2014-02-06
UA115561C2 (uk)	2017-11-27
CN104428302B (zh)	2017-03-22
UY34955A (es)	2014-01-31
AR091939A1 (es)	2015-03-11
KR20150037950A (ko)	2015-04-08
JP2015523406A (ja)	2015-08-13
MA37798B1 (fr)	2018-11-30
US20140045856A1 (en)	2014-02-13
US9085584B2 (en)	2015-07-21
EA028958B1 (ru)	2018-01-31
EA201500182A1 (ru)	2015-07-30
CL2015000096A1 (es)	2015-06-19
BR112015002118A2 (pt)	2017-07-04
AU2013298621B2 (en)	2017-12-21
EP2882749B1 (en)	2018-04-04
CN104428302A (zh)	2015-03-18
AU2013298621A1 (en)	2015-02-05
JP6356671B2 (ja)	2018-07-11
EP2882749A1 (en)	2015-06-17
TN2015000022A1 (en)	2016-06-29
HK1208440A1 (en)	2016-03-04
SG11201500772VA (en)	2015-02-27
PH12015500211A1 (en)	2015-03-16
CO7310531A2 (es)	2015-06-30
PH12015500211B1 (en)	2015-03-16
US20140045857A1 (en)	2014-02-13

Publication	Publication Date	Title
HK1208440A1 (en)	2016-03-04	4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes 4--23599b--[a]
SG10201406545TA (en)	2014-11-27	A well
EP2611352A4 (en)	2014-06-04	DISHWASHER
GB2508701B (en)	2017-09-06	A knee-walker
HK1192757A1 (zh)	2014-08-29	取代的 -芳基- -苯基- -三嗪- -胺
GB201223264D0 (en)	2013-02-06	A hydrogen-storage-material
GB201007327D0 (en)	2010-06-16	A fireseal
KR101209432B9 (ko)	2023-04-17	복근재활기구
EP2893202A4 (en)	2016-04-27	STAPLE
GB201002966D0 (en)	2010-04-07	A bedchair
GB2510464B (en)	2017-07-05	A Footgauge
GB201201920D0 (en)	2012-03-21	A tie
AU2012900615A0 (en)	2012-03-08	A bar assembly
GB2506132B (en)	2014-11-19	A fuseboard
GB2507995B (en)	2015-08-26	A hand sanitiser
GB2501262B (en)	2014-05-14	A top
AU2012905507A0 (en)	2013-01-10	A reinforcing bar assembly
AU2012904993A0 (en)	2012-11-29	A fastener
AU2012902838A0 (en)	2012-07-19	A i
ZA201305468B (en)	2014-06-25	Connecting mechanisms for a guy-wire
AU2012903846A0 (en)	2012-09-20	A printer arrangement
ZA201208126B (en)	2013-06-26	A biodigester
HK1166580A2 (en)	2012-11-02	A lacelock
AU2012905412A0 (en)	2013-01-10	A bat
GB201200072D0 (en)	2012-02-15	A glycerin-gas-fuel-emulsion